[A26-88] Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2026
Project no.:
A26-88
Commission:
Commission awarded on 15.07.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI:
https://doi.org/10.60584/A26-88
| Project no. | Title | Status |
|---|---|---|
| A18-61 | Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-56 | Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-100 | Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-101 | Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |